RS97703A - Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds - Google Patents

Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds

Info

Publication number
RS97703A
RS97703A YU97703A YUP97703A RS97703A RS 97703 A RS97703 A RS 97703A YU 97703 A YU97703 A YU 97703A YU P97703 A YUP97703 A YU P97703A RS 97703 A RS97703 A RS 97703A
Authority
RS
Serbia
Prior art keywords
compounds
medicament
production
side chain
acid amides
Prior art date
Application number
YU97703A
Other languages
English (en)
Inventor
Joachim Brendel
Thomas Bohme
Stefan Peukert
Heinz-Werner Kleemann
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Publication of RS97703A publication Critical patent/RS97703A/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjejnja formule I, u kojoj R(1) do R(7) imaju značenja koja su navedena u patentnim zahtevima. Ova jedinjenja deluju na Kv 1,5-kalijumov kanal i inhibiraju kalijumovu struju u srčanoj predkomori ljudi, koja je označena kao "ultra-rapidly activating delayed rectifier". Ova jedinjenja su zbog toga naročito pogodna da se koriste kao nove aktivne supstance protiv aritmija, specijalno za lečenje i profilaksu aritmija srčane predkomore, na primer atrialne fibrilacije (AF) ili lepršanja srčane predkomore (atriales Flattern).
YU97703A 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds RS97703A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (1)

Publication Number Publication Date
RS97703A true RS97703A (en) 2006-12-15

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
YU97703A RS97703A (en) 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds

Country Status (41)

Country Link
US (2) US6903216B2 (sr)
EP (1) EP1399423B9 (sr)
JP (1) JP4422477B2 (sr)
KR (1) KR100863924B1 (sr)
CN (1) CN1247544C (sr)
AR (1) AR036045A1 (sr)
AT (1) ATE378318T1 (sr)
AU (1) AU2002316939B2 (sr)
BG (1) BG108415A (sr)
BR (1) BR0210374A (sr)
CA (1) CA2450076C (sr)
CO (1) CO5540283A2 (sr)
CR (1) CR7140A (sr)
CY (1) CY1107427T1 (sr)
CZ (1) CZ20033361A3 (sr)
DE (2) DE10128331A1 (sr)
DK (1) DK1399423T3 (sr)
EC (1) ECSP034883A (sr)
EE (1) EE05196B1 (sr)
ES (1) ES2295360T3 (sr)
HK (1) HK1065316A1 (sr)
HR (1) HRP20031028A2 (sr)
HU (1) HUP0400159A3 (sr)
IL (2) IL159247A0 (sr)
MA (1) MA27037A1 (sr)
MX (1) MXPA03010875A (sr)
MY (1) MY138341A (sr)
NO (1) NO20035450D0 (sr)
NZ (1) NZ530081A (sr)
OA (1) OA12631A (sr)
PE (1) PE20021066A1 (sr)
PL (1) PL364371A1 (sr)
PT (1) PT1399423E (sr)
RS (1) RS97703A (sr)
RU (1) RU2293727C2 (sr)
SK (1) SK15222003A3 (sr)
TN (1) TNSN03134A1 (sr)
TW (1) TWI304400B (sr)
UA (1) UA75412C2 (sr)
WO (1) WO2002100825A2 (sr)
ZA (1) ZA200308520B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
KR20040104643A (ko) * 2002-04-26 2004-12-10 이시하라 산교 가부시끼가이샤 피리딘계 화합물 또는 이의 염 및 이들을 함유하는 제초제
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
PT1651621E (pt) 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
WO2007124849A2 (en) * 2006-04-27 2007-11-08 Sanofi-Aventis Deutschland Gmbh Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
DK2448909T3 (da) * 2009-06-29 2013-07-15 Merz Pharma Gmbh & Co Kgaa Fremgangsmåde til fremstilling af 1-amino-1,3,3,5,5-pentamethylcyclohexan
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (sr) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
EP3680232A4 (en) * 2017-08-07 2021-08-11 Hiroshima University NEW COMBINATION BASED ON ANTHRANIC ACID AND PIN1 INHIBITOR, THERAPEUTIC FOR INFLAMMATORY DISEASES AND THERAPEUTIC FOR CANCER WITH IT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
DE69928260T2 (de) * 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
BR0011571A (pt) * 1999-06-24 2002-03-05 Smithkline Beecham Corp Antagonistas do receptor de limpeza de macrófago
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
ES2295360T3 (es) 2008-04-16
ATE378318T1 (de) 2007-11-15
TWI304400B (en) 2008-12-21
BG108415A (en) 2004-07-30
EP1399423B9 (de) 2008-02-27
DE10128331A1 (de) 2002-12-19
HUP0400159A2 (hu) 2004-07-28
HRP20031028A2 (en) 2005-10-31
MA27037A1 (fr) 2004-12-20
CO5540283A2 (es) 2005-07-29
KR100863924B1 (ko) 2008-10-17
US7235664B2 (en) 2007-06-26
HK1065316A1 (en) 2005-02-18
MY138341A (en) 2009-05-29
IL159247A0 (en) 2004-06-01
KR20040030668A (ko) 2004-04-09
CA2450076C (en) 2010-11-30
PT1399423E (pt) 2008-02-07
NZ530081A (en) 2005-07-29
CY1107427T1 (el) 2012-12-19
CN1529695A (zh) 2004-09-15
EE05196B1 (et) 2009-08-17
CR7140A (es) 2004-04-15
TNSN03134A1 (en) 2005-12-23
US20030114499A1 (en) 2003-06-19
JP4422477B2 (ja) 2010-02-24
EP1399423A2 (de) 2004-03-24
DK1399423T3 (da) 2008-03-17
DE50211213D1 (de) 2007-12-27
EP1399423B1 (de) 2007-11-14
MXPA03010875A (es) 2004-02-17
AU2002316939B2 (en) 2006-11-23
BR0210374A (pt) 2004-07-13
CN1247544C (zh) 2006-03-29
WO2002100825A3 (de) 2003-12-11
CZ20033361A3 (cs) 2004-05-12
UA75412C2 (en) 2006-04-17
HUP0400159A3 (en) 2008-10-28
ZA200308520B (en) 2004-09-06
US20050137200A1 (en) 2005-06-23
SK15222003A3 (sk) 2004-06-08
AR036045A1 (es) 2004-08-04
WO2002100825A2 (de) 2002-12-19
OA12631A (fr) 2006-06-14
PL364371A1 (en) 2004-12-13
ECSP034883A (es) 2004-01-28
JP2004533464A (ja) 2004-11-04
EE200300558A (et) 2004-02-16
IL159247A (en) 2010-06-16
US6903216B2 (en) 2005-06-07
RU2293727C2 (ru) 2007-02-20
NO20035450D0 (no) 2003-12-08
CA2450076A1 (en) 2002-12-19
PE20021066A1 (es) 2003-01-21
RU2004100302A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
RS97703A (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds
TNSN03084A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
HK1066539A1 (en) Ortho-substituted nitrogen-containing bisaryl compounds use as potassium channel inhibitors
YU42503A (sh) Arilovani furan-1 tiofen-amidi-karbonske kiseline sa blokirajućim dejstvom kalijumovog kanala
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CY1106178T1 (el) 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν
GR3036184T3 (en) Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
WO2022238565A3 (en) Modulators of sortilin activity
BR0206791A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
TW200407290A (en) Pentafluorosulfanylbenzoylguanidines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
CA2529441A1 (en) Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2023154804A3 (en) Method of treating spinal cord injury and composition for use therein
UA84307C2 (ru) Пентафторсульфанил-бензоилгуанидины, способ их получения, их применение как лекарственных или диагностических средств, а также лекарственные средства, которые их содержат
WO2024006974A3 (en) Antimalarial compounds
WO2021125910A3 (ko) NDPK 활성제 및 H-prune 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
RU2002108691A (ru) Состав для консервирования мяса